Semaglutide, the active ingredient in Ozempic, has been linked to a lower risk of stroke and dementia in people with type 2 diabetes. The evidence is observational and does not show that the drug protects the brain. A large randomised trial in people who already had Alzheimer’s found no slowing of the disease.
What Do Studies Say About Semaglutide and Alzheimer’s Risk?
A study in Alzheimer’s & Dementia found semaglutide was associated with a 40% to 70% lower risk of first-time Alzheimer’s diagnosis compared with seven other diabetes medications. A later analysis of more than 1.7 million US patients reported a significantly reduced risk of Alzheimer’s disease-related dementia versus insulin, metformin and older GLP-1 drugs.
The protective signal was strongest for vascular dementia, with no significant association for frontotemporal or Lewy body dementias.
Is Semaglutide Linked to a Lower Risk of Stroke?
Research published in JAMA Network Open found that semaglutide and tirzepatide users with type 2 diabetes and obesity had a lower risk of neurodegenerative disease and cerebrovascular disease, including stroke, than people taking similar medications. The authors called for further clinical trials to confirm the findings.
Did Semaglutide Slow Alzheimer’s in Clinical Trials?
No. Novo Nordisk’s EVOKE and EVOKE+ phase 3 trials enrolled 3,808 people aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer’s. Oral semaglutide did not significantly slow disease progression on the primary endpoint compared with placebo, although Alzheimer’s-related biomarkers improved.
In the EVOKE trial, patients on semaglutide and placebo both advanced by an average of 2.2 points on the clinical scale after two years.
Why Do Observational Studies and the Trial Differ?
The studies ask different questions:
- Prevention versus treatment. The observational studies look at first-time diagnoses in people with diabetes. EVOKE tested whether the drug could slow Alzheimer’s once symptoms had begun. The trial does not settle whether earlier or longer treatment would help.
- Vascular benefits. The strongest signal appeared for vascular dementia and stroke. The researchers noted the link could reflect semaglutide’s improvement of risk factors such as type 2 diabetes, obesity and cardiovascular disease, rather than a direct effect on Alzheimer’s pathology.
- Confounding. Patients prescribed one diabetes drug over another can differ in ways that medical records do not capture.
- Diagnostic coding. The dementia analyses relied on diagnostic codes, which are subject to underdiagnosis and misclassification.
What Do Experts Say?
Alberto Espay of the University of Cincinnati, who was not involved in the research, noted that early studies of statins and insulin also showed promise but did not pan out as treatments, and urged caution about claiming semaglutide can treat or prevent Alzheimer’s.
What Does this Mean for Patients?
The current evidence does not support taking semaglutide to protect brain health. Side effects such as nausea, vomiting and diarrhoea remain, and long-term safety for brain protection needs more study.
For people already prescribed the drug for diabetes or obesity, any brain benefit would be a possible extra. The best-established ways to lower stroke and vascular dementia risk remain controlling blood pressure, blood sugar and weight, staying physically active and not smoking. People concerned about their risk should consult a doctor.
Frequently Asked Questions
Does Ozempic reduce the risk of stroke?
Large observational studies link semaglutide to fewer strokes in people with type 2 diabetes. They show association, not proof of cause.
Can Ozempic prevent Alzheimer’s disease?
This is unproven. Semaglutide did not slow progression in two phase 3 trials of early symptomatic Alzheimer’s.
Does Ozempic protect against all types of dementia?
No. The strongest association was with vascular dementia. No significant link was found for frontotemporal or Lewy body dementias.
Should people take Ozempic for brain health?
No. Semaglutide is approved for diabetes and weight management, and the brain-health findings need confirmation in randomised trials.
